Omecamtiv Mecarbil

Omecamtiv mecarbil is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction. It is being evaluated as a potential treatment of heart failure in both intravenous and oral formulations with application across the continuum of care for heart failure patients from in-hospital to outpatient settings.

Omecamtiv mecarbil is now in a broad clinical trials program designed to evaluate this novel drug candidate in a variety of patients with heart failure. For more information regarding the ongoing and completed clinical trials, please visit the links below:


Phase II Clinical Trials  Details

Phase I Clinical Trials  Details